Pharmacogenomics explained: how genes affect medication response

What pharmacogenomics is

Pharmacogenomics is the study of how genetic variation affects a person’s response to medications — how quickly a drug is metabolised, how effective it is, and how likely it is to cause side effects. Over 90% of people carry a variant that changes how they respond to a commonly prescribed medicine.

Why this is more established than most genetics-and-health topics

Unlike many areas of consumer genetics, pharmacogenomics has direct clinical infrastructure behind it. CPIC (the Clinical Pharmacogenetics Implementation Consortium) publishes hospital-grade prescribing and dosing guidelines — currently spanning 59 genes and 420 guidelines — and PharmGKB catalogues evidence-graded drug-gene interactions across roughly 70 well-studied genetic positions and 466 drug pairs. These aren’t consumer-wellness resources; they are built for and used by clinicians and pharmacists.

How DNA Layer uses this data

CPIC and PharmGKB are part of DNA Layer’s always-on clinical-grade safety floor, alongside ClinVar, ClinGen Actionability, and FDA pharmacogenomic labels. This floor is checked for every report regardless of which optional sources a given report enables, can only raise a finding’s flagged severity (never lower it), and never invents a finding — so a real prescribing-relevant result is never understated. See how DNA Layer builds your report for the full methodology.

What this isn’t

A pharmacogenomic finding is not a prescription and not a substitute for your doctor’s or pharmacist’s guidance — it’s information you can bring to that conversation. Never change or stop a medication based on a genetic report without talking to a qualified healthcare professional first.